A detailed history of Capital Performance Advisors LLP transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Capital Performance Advisors LLP holds 6,231 shares of BMY stock, worth $291,673. This represents 0.05% of its overall portfolio holdings.

Number of Shares
6,231
Previous 4,613 35.07%
Holding current value
$291,673
Previous $213,000 31.92%
% of portfolio
0.05%
Previous 0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 22, 2025

BUY
$43.31 - $48.98 $70,075 - $79,249
1,618 Added 35.07%
6,231 $281,000
Q2 2025

Aug 04, 2025

SELL
$44.12 - $59.6 $105,226 - $142,146
-2,385 Reduced 34.08%
4,613 $213,000
Q1 2025

May 09, 2025

BUY
$53.9 - $63.11 $43,766 - $51,245
812 Added 13.13%
6,998 $426,000
Q4 2024

Jan 31, 2025

BUY
$51.92 - $59.94 $63,602 - $73,426
1,225 Added 24.69%
6,186 $349,000
Q3 2024

Nov 01, 2024

BUY
$39.66 - $51.75 $196,753 - $256,731
4,961 New
4,961 $256,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $99.5B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Capital Performance Advisors LLP Portfolio

Follow Capital Performance Advisors LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Performance Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Capital Performance Advisors LLP with notifications on news.